#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Brain stem glioma Pancreatic carcinoma metastatic Renal transplant Infection in an immunocompromised host Focal segmental glomerulosclerosis Nephropathy Head and neck cancer Fragile X syndrome Congenital myopathy Neurofibroma Mastocytosis Neoplasm Cerebral amyloid angiopathy Leber's congenital amaurosis Pericarditis More trials…

    Learn about Rare Diseases

    Prader-Willi syndrome – Treatment Sarcoidosis – Treatment Angiosarcoma recurrent – Treatment Fabry’s disease – Life with Disease Carcinoid syndrome – Life with Disease Metachromatic leukodystrophy – Treatment Lennox-Gastaut syndrome – Basic Information Kearns-Sayre syndrome – Basic Information Primary mediastinal large B-cell lymphoma – Trials in Disease Cystic fibrosis lung – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Calcium Folinate Pentahydrate VANDETANIB Tak-280 (-)-PHENSERINE TARTRATE Budesonide Salmeterol Xinafoate Cefixime Trihydrate Carbasalate Calcium GSK5764227 Tigulixostat Alectinib Hydrochloride Pariglasgene Brecaparvovec Wve-006 Terbinafine Hydrochloride Poa Pratensis Pollen Extract TUB-030 Imatinib Mesilate Estradiol Hemihydrate Leflunomide Metoprolol Tartrate More therapies…

    Learn about Your Condition

    Neurogenic bladder Breast angiosarcoma Deep vein thrombosis Erosive oesophagitis Sexual dysfunction Endometriosis Chronic granulomatous disease Endometrial adenocarcinoma Chondrosarcoma Hypothyroidism Tendon rupture Metabolic syndrome Lymphoedema Vasospasm Acute respiratory failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Bortezomib
    • Daratumumab
    • Dexamethasone
    Belgium Denmark France Germany Greece Italy +4

  • Study on the Long-Term Safety of Sacituzumab Govitecan for Patients with Metastatic Solid Tumors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Sacituzumab Govitecan
    Belgium France Spain

  • Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

    Not recruiting

    3 1
    Investigated Drugs:
    • Obicetrapib
    Bulgaria Croatia Czechia Denmark Finland Germany +7

  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Emtricitabine
    • Entecavir
    • Ianalumab
    Austria Belgium Bulgaria Czechia France Germany +10

  • Study on Ruxolitinib and Drug Combination for Critically Ill Adults with Acquired Hemophagocytic Syndrome

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Etoposide
    • Lidocaine Hydrochloride Monohydrate
    France

  • Study Comparing Zimberelimab and Domvanalimab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Domvanalimab
    • Zimberelimab
    • Pembrolizumab
    France Greece Ireland Spain
Previous Page
1 … 1,690 1,691 1,692 1,693 1,694 1,695
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!